JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

计划入组 13 人 · 首次发布于 2023 年 8 月 21 日

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

计划入组 24 人 · 首次发布于 2016 年 5 月 3 日

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

计划入组 17 人 · 首次发布于 2018 年 8 月 13 日

JAK1 inhibitor 36b (Ewha Womans University)

JAK1/TYK2 inhibitors(Pfizer)

TYK2 inhibitor

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

JAK Inhibitors Show Promise in Treating Alopecia Areata

JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasms Through Novel Mechanisms

New Phase 1 Trial Combines Tagraxofusp and Pacritinib for Treatment-Resistant Myelofibrosis